Sichenzia Ross Friedman Ference LLP Represents Citius Pharmaceuticals Inc. in connection with its acquisition of LM Biosciences, Inc.
Press Release – New York, NY – March 8, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that it has represented Citius in its acquisition of LM Biosciences, Inc. (“LMB”). LMB is a late-stage specialty pharmaceutical company focused on the development and commercialization of critical care products with a concentration of anti-infective drugs.
The acquisition was an all stock transaction and included a $3 million investment by Citius’ Chairman of the Board. The Sichenzia Ross Friedman Ference LLP was led by Partners Arthur Marcus, Gregory Sichenzia and associate Nazia Khan.
- Sichenzia Ross Ference LLP Represents EzFill in $28.75 Million Initial Public Offering and NASDAQ Listing - September 20, 2021
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $81 Million Underwritten Public Offering for Farmmi, Inc. - September 15, 2021
- Sichenzia Ross Ference LLP Secures Deferred Prosecution Agreement for Client Under Federal Indictment in the Southern District of New York - September 13, 2021